
# Adult and pediatric IV push medication reference

June 2023



#### **Purpose**

The purpose of this document is 2-fold:

- 1) to provide a list of medications commonly administered as intravenous (IV) push or slow IV injection
- 2) to provide a list of medications that can be administered as IV push or slow IV injection to supplement drug shortage mitigation strategies in the setting of bulk IV fluid shortages.

The list of medications provided is not all-inclusive. Clinical judgment and assessment of appropriateness is recommended at the institutional level and may differ based on the clinical scenario (eg, code situations).

#### Methodology

To provide the 2022 update to this reference, Vizient subject matter experts met to identify medications that are commonly administered via IV push or have recently experienced a drug shortage. From this initial list of 34 medications, IV push or slow IV injection information was obtained and verified with multiple tertiary resources. Once the medication information was collected, Vizient subject matter experts met again to reach consensus on which medications had appropriate literature support for addition to the list. In total, 25 additional medications met criteria to be added the reference list. In 2023, pediatric information was added for medications with available guidance. The list is not inclusive of neonatal administration information. Please refer to the appropriate clinical resources for neonatal information.

#### Mitigation strategies to conserve IV fluids

This document provides guidance on how members can take advantage of administering medications via IV push or slow IV injection; we have also noted where alternate routes—such as oral (PO) or intramuscular (IM) administration—are an option.

There are several additional strategies that members may wish to implement to conserve IV fluids, including:

- · transitioning patients to an oral equivalent when clinically appropriate
- administration of a more concentrated (smaller volume) product wherever possible
- increasing "hang" time of IV fluids
- a summary of <u>mitigation strategies</u> was published by the American Society of Health-System Pharmacy (ASHP)
- discontinuing "to keep open (TKO)" practice and using intermittent line flushing for maintaining patency
- a full list of Vizient mitigation strategies can be accessed on the Vizient website at <u>Drug shortage mitigation strategies</u>

#### Safety considerations

Surveys <u>conducted by the Institute for Safe Medication Practices</u> (ISMP) have highlighted a number of unsafe practices associated with administering medications IV push, including improper dilution and use of prefilled normal saline flush syringes to dilute medications (often without syringe relabeling).

In recognizing a lack of available guidance and standardized safe practices associated with IV push administration, the ISMP released the <a href="ISMP Safe Practice Guidelines for Adult IV Push Medications">ISMP Safe Practice Guidelines for Adult IV Push Medications</a> and also published <a href="updated guidance">updated guidance</a> following their survey conducted in 2018. ISMP has a <a href="Gap Analysis Tool for Safe IV Push Medication Practices">Gap Analysis Tool for Safe IV Push Medication Practices</a> available.

These resources developed by ISMP provide guidance around identifying and targeting the risks associated with current practices that may exist at member institutions, as well as establishing safe and best practices and providing education to healthcare providers.

#### Medications with literature support for IV push or slow IV injection<sup>a</sup>

| Medication            | Instructions for reconstitution                          | Dilution instructions for IVP/slow IV inj.   | Administration time for IVP/slow IV inj.   | Remarks   |
|-----------------------|--|--|--|---|
| Acid suppressants     |  |  |  |   |
| Esomeprazole (Nexium) | 40 mg vial: reconstitute powder with 5 mL NS, LR, or D5W | No additional dilution is necessary  | Adult: Administer over at least 3 min  Pediatric: No data  | <ul> <li>Flush line prior to and after administration with NS, LR, or D5W.</li> <li>IV push administration is approved for treatment of GERD.</li> <li>The manufacturer recommends that pediatric patients receive IV esomeprazole by intermittent IV infusion only.</li> </ul> |
| Famotidine (Pepcid)   | 20 mg vial: supplied as solution for injection           | May administer undiluted or dilute 20 mg (2 mL) vial with NS or another compatible diluent to a total volume of 5 to 10 mL | Adult: Administer over at least 2 min and no faster than 10 mg/min  Pediatricb: 2 mg/mL over at least 2 min and no faster than 10 mg/min | None of note  |

| Medication               | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj.  | Administration time for IVP/slow IV inj.   | Remarks  |
|--------------------------|---|---|--|--|
| Pantoprazole (Protonix)  | <b>40 mg vial</b> : reconstitute with 10 mL NS  | No additional dilution is necessary   | Adult: Administer over at least 2 min  Pediatricb: 4 mg/mL over at least 2 min   | Flush IV line before and after administration with D5W, NS, or LR.   |
| Analgesics               | •   |   |  |  |
| Fentanyl (Sublimaze)     | Supplied as ampules, vials, prefilled syringes, and cartridges supplied as solution for injection   | May administer undiluted  | Adult: Administer over 1 to 2 min  Pediatric <sup>b</sup> : 10 to 50 mcg/mL over at least 3 to 5 min; larger doses over 5 to 10 minutes                  | Rapid administration may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. Additional monitoring required.  |
| Hydromorphone (Dilaudid) | Extreme caution should be used to avoid confusion of the highly concentrated injectable product with the less concentrated injectable product | <ul> <li>For the less concentrated formulation - no additional dilution is necessary</li> <li>For high-potency formulation, reconstitute with 25 mL of SWFI to a concentration of 10 mg/mL</li> </ul> | Adult: Administer over 2 to 3 min  Pediatric <sup>b</sup> : Same as adult  | Rapid administration been associated with an increase in adverse events, especially respiratory depression and hypotension. Additional monitoring required.  |
| Ketorolac (Toradol)      | 15 mg and 30 mg vials:<br>supplied as solution for<br>injection; 60 mg/2 mL vials for<br>IM injection only                                    | No dilution is necessary  | Adult: Administer over 15 s; may also be administered as a slow IV injection distributed evenly over 1 to 2 min.  Pediatricb: administer over 1 to 5 min | Monitor for signs and symptoms of gastrointestinal upset or bleeding.  |
| Morphine                 | Supplied as prefilled syringes and cartridges supplied as solution for injection  | May dilute to a final concentration of 0.5 to 5 mg/mL   | Adult: Administer over 4 to 5 min  Pediatricb: 0.5 to 5 mg/mL over 4 to 5 min  | Products are designed for administration by specific routes. Rapid administration may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. Additional monitoring required. |

| Medication              | Instructions for reconstitution  | Dilution instructions for IVP/slow IV inj.   | Administration time for IVP/slow IV inj.   | Remarks  |
|-------------------------|--|--|--|--|
| Anesthetics / Sedatives |  |  |  |  |
| Diazepam (Valium)       | Supplied as vials, prefilled syringes, and cartridges supplied as solution for | Do not dilute  | Adult: Administer no faster than 5 mg/min  Pediatricb: Administer over at  | Avoid smaller veins to reduce incidence of venous thrombosis, phlebitis, or local  |
|                         | injection  |  | least 3 min; rate should not exceed 2 mg/min   | irritation.  |
| Etomidate (Amidate)     | Supplied as vials, ampuls, and syringes as solution for injection              | Do not dilute  | Adult: Administer over 30 to 60 s  Pediatric <sup>b</sup> : Same as adult  | For general anesthesia induction or procedural sedation. Should be administered by or under the direct supervision of persons trained in administration and management of complications with general anesthesia. |
| Lorazepam (Ativan)      | Supplied as vials, and syringe cartridges as solution for injection            | Dilute with SWFI, NS, or D5W. Dilute with an equal volume of compatible solution immediately prior to use.           | Adult: Administer over at least 2 min; should not exceed 2 mg/min or 0.05 mg/kg  Pediatricb: Same as adult   | Avoid smaller veins to reduce incidence of venous thrombosis, phlebitis, or local irritation.  |
| Midazolam (Versed)      | Supplied as vials as solution for injection                                    | For procedural / sedation / anxiolysis use a 1 mg/mL concentration or a dilution of the 1 or 5 mg/mL concentrations. | Adult: For procedural sedation / anxiolysis / amnesia administer over at least 2 min   | For general anesthesia induction or procedural sedation should be  |
|                         |  |  | For induction of anesthesia administer over 5 to 15 s  | administered by or under the direct supervision of persons trained in administration and management of complications with general anesthesia.  |
|                         |  |  | Pediatric <sup>b</sup> : 1 or 5 mg/mL given<br>over 20 to 30 s for anesthesia<br>induction; should not be<br>administered faster than 2 min<br>in neonates |  |
| Antibiotics             |  |  |  |  |
| Ampicillin              | 125, 250, and 500 mg vials:<br>reconstitute with 5 mL SWFI or<br>BWFI          | No additional dilution necessary   | Adult: Administer doses ≤ 500 mg over 3 to 5 min   | Solutions must be used within 1 h of reconstitution  |
|                         | DWFI   | over 10 to 15 min  |  | Administering ampicillin more rapidly than recommended   |
|                         |  |  | Pediatric <sup>b</sup> : Same as adult   | may result in seizures   |

| Medication            | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj.           | Administration time for IVP/slow IV inj.                  | Remarks   |
|-----------------------|---|--|---|---|
|                       | 1 g and 2 g vials: reconstitute<br>with 7.4 mL or 14.8 mL SWFI<br>or BWFI, respectively |  |   |   |
| Aztreonam (Azactam)   | 1 g and 2 g vials: reconstitute with 6 to 10 mL SWFI;                                   | No additional dilution necessary                     | Adult: Administer over 3 to 5 min                         | None of note  |
|                       | immediately shake vigorously  |  | Pediatric <sup>b</sup> : Same as adult                    |   |
| Cefazolin             | <b>500 mg vial</b> : reconstitute with 2 mL SWFI. Shake well.                           | Further dilute reconstituted solution with 5 mL SWFI | Adult: Administer over 3 to 5 min                         | None of note  |
|                       | Final conc. = 225 mg/mL   |  | Pediatric <sup>b</sup> : Same as adult and                |   |
|                       | 1 g vial: reconstitute with 2.5 mL SWFI. Shake well.                                    |  | further dilute to a maximum concentration of 100 mg/mL    |   |
|                       | Final conc. = 330 mg/mL   |  |   |   |
| Cefotaxime (Claforan) | 500 mg, 1 g, and 2 g vials:<br>reconstitute with 10 mL SWFI                             | No additional dilution necessary                     | Adult: Administer over 3 to 5 min                         | Avoid rapid injection (< 1 min) due to association with arrhythmias |
|                       | Final conc. = 50, 95, and 180 mg/mL, respectively                                       |  | Pediatric <sup>b</sup> : 180 to 200 mg/mL over 3 to 5 min |   |
| Cefotetan (Cefotan)   | 1 g vial: reconstitute with 10 mL SWFI  | No additional dilution necessary                     | Adult: Administer over 3 to 5 min                         | None of note  |
|                       | Final conc. = 95 mg/mL  |  | Pediatric <sup>b</sup> : ≤ 182 mg/mL over 3 to 5 min      |   |
|                       | 2 g vial: reconstitute with 10 to 20 mL SWFI  |  |   |   |
|                       | Final conc. = 182 or 95 mg/mL, respectively   |  |   |   |
| Cefoxitin             | 1 g vial: reconstitute with 10 mL SWFI, BWFI, NS, or D5W                                | No additional dilution necessary                     | Adult: Administer over 3 to 5 min                         | None of note  |
|                       | Final conc. = 95 mg/mL  |  | Pediatricb: 180 mg/mL over 3                              |   |
|                       | 2 g vial: reconstitute with 10 or 20 mL SWFI, BWFI, NS, or D5W                          |  | to 5 min  |   |
|                       | Final conc. = 180 or 95 mg/mL, respectively   |  |   |   |

| Medication                       | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj. | Administration time for IVP/slow IV inj.   | Remarks   |
|----------------------------------|---|--|--|---|
| Ceftazidime (Fortaz, Tazicef)    | 500 mg vial: reconstitute with 5.3 mL SWFI  Fortaz final conc. = 100 mg/mL  1 g and 2 g vials: reconstitute with 10 mL SWFI  Fortaz or generic final conc. = 100 and 170 mg/mL, respectively  Tazicef final conc. = 95 and 180 mg/mL, respectively  | No additional dilution necessary           | Adult: Administer over 3 to 5 min  Pediatricb: 100 to 170 mg/mL over 3 to 5 min  | None of note  |
| Cefuroxime                       | 750 mg vial: reconstitute with 8.3 mL SWFI  1.5 g vial: reconstitute with 16 mL SWFI  Final conc. = 90 mg/mL  | No additional dilution necessary           | Adult: Administer over 3 to 5 min  Pediatricb: 90 mg/mL over 3 to 5 min          | None of note  |
| Chloramphenicol                  | 1 g vial: reconstitute with 10 mL SWFI or D5W  Final conc. = 100 mg/mL  | No additional dilution necessary           | Adult: Administer over at least 1 min  Pediatricb: 100 mg/mL over at least 1 min | None of note  |
| Colistimethate sodium            | 150 mg vial: reconstitute with 2 mL SWFI; swirl gently to avoid frothing  Final conc. = 75 mg/mL colistin base activity   | No additional dilution necessary           | Adult: Administer over 3 to 5 min  Pediatricb: Same as adult                     | The 2019 International Consensus Guidelines for the Optimal Use of the Polymixins advise administration over 0.5 to 1 h                                   |
| Daptomycin (Cubicin, Cubicin RF) | Generic 350 mg vial: reconstitute with 7 mL NS. Allow to stand for 10 min, then gently swirl to obtain completely reconstituted solution. Do not shake or agitate vial vigorously.  Cubicin and generic 500 mg vials: reconstitute with 10 mL NS. Allow to stand for 10 min, then gently swirl to obtain completely reconstituted | No additional dilution is necessary        | Adult: Administer over at least 2 min  Pediatric: No data                        | Use of saline-based diluents to reconstitute Cubicin RF results in hyperosmotic solution that may cause infusion site reactions when administered IV push |

| Medication              | Instructions for reconstitution  | Dilution instructions for IVP/slow IV inj.             | Administration time for IVP/slow IV inj.  | Remarks   |
|-------------------------|--|--|---|---|
|                         | solution. Do not shake or agitate vial vigorously.   |  |   |   |
|                         | Cubicin RF 500 mg vials: reconstitute with 10 mL SWFI or BWFI (do NOT use NS). Rotate or swirl vial for a few minutes, as needed, to reconstitute. |  |   |   |
|                         | Final conc., all products. = 50 mg/mL  |  |   |   |
| Meropenem (Merrem)      | 500 mg vial: reconstitute with 10 mL SWFI  | No additional dilution is necessary                    | Adult: Administer over 3 to 5 min   | None of note  |
|                         | 1 g vial: reconstitute with 20 mL SWFI   |  | Pediatric <sup>b</sup> : 50 mg/mL over 3 to 5 min   |   |
| Nafcillin               | 1 g vial: reconstitute with 3.4 mL SWFI, BWFI, or NS   | Further dilute with 15 to 30 mL<br>SWFI or NS prior to | Adult: Administer over 5 to 10 min  | Vesicant. Caution extravasation.  |
|                         | 2 g vial: reconstitute with 6.6 mL SWFI, BWFI or NS  | administration (applies to both vial sizes)            | Pediatric <sup>b</sup> : Administer appropriate dose in 15 to 30  | Caution phlebitis.  |
|                         | Final conc., both vial sizes= 250 mg/mL  |  | mL of diluent over 5 to 10 min  |   |
| Oxacillin               | 1 g vial: reconstitute with 10 mL of SWFI or NS; shake well  | No additional dilution is necessary                    | Adult: Administer over at least 10 min  | Caution phlebitis.  |
|                         | 2 g vial: Add 20 mL of SWFI or NS; shake well  |  | Pediatric <sup>b</sup> : Same as adult  |   |
| Antiemetics             |  |  |   |   |
| Metoclopramide (Reglan) | Supplied as vials and prefilled syringes as solution for injection   | Doses ≤ 10 mg may be given undiluted                   | Adult: Administer doses ≤ 10<br>mg undiluted as an IV push<br>over at least 2 min<br>Pediatric <sup>b</sup> : Same as adult | Doses > 10 mg should be<br>diluted in 50 mL compatible<br>solution (preferably NS) and<br>administered via IV piggyback<br>over at least 15 min |

| Medication                      | Instructions for reconstitution  | Dilution instructions for IVP/slow IV inj.                 | Administration time for IVP/slow IV inj.   | Remarks   |
|---------------------------------|--|--|--|---|
| Ondansetron (Zofran)            | Supplied as vials as solution for injection  | Administer undiluted                                       | Adult: Administer over at least 30 s, but preferably over 2 to 5 min   | IV push is given for PONV only (single doses)   |
|                                 |  |  | Pediatric <sup>b</sup> : In children < 40 kg<br>receiving 0.1 mg/kg administer<br>over at least 30 s, but 2 to 5<br>min is preferred |   |
| Cardiovascular agents           |  |  |  |   |
| Diltiazem (Cardizem)            | Supplied as vials as solution  | Administer undiluted                                       | Adult: Administer over 2 min   | Continuous ECG and blood  |
|                                 | for injection. ADD-Vantage powder vials should be reconstituted with 100 mL D5W or NS. |  | Pediatric <sup>b</sup> : 5 mg/mL over 2 to 5 min   | pressure monitoring required  |
| Enalaprilat (Vasotec)           | Supplied as vials as solution for injection  | May be administered undiluted                              | Adult: Administer evenly distributed over 5 min  | Monitor for precipitous blood pressure drop with first dose   |
|                                 |  |  | Pediatricb: Same as adult  |   |
| Hydralazine                     | Supplied as vials as solution  | Administer undiluted                                       | Adult: Administer over 1 min   | Monitor blood pressure every 5 min until at desired level. Check every 15 min thereafter throughout crisis.                               |
|                                 | for injection  |  | Pediatric <sup>b</sup> : Administer over 1 to 2 min and no faster than 5 mg/min  |   |
| Labetalol                       | Supplied as vials, cartridges, and premixed bags as solution for injection             |  | Adult: Administer over at least 2 min and no faster than 10 mg/min   | Although initial bolus dose is often followed by a continuous infusion, providers may instead   |
|                                 |  |  | Pediatric <sup>b</sup> : 5 mg/mL over 2 to 3 min and no faster than 2 mg/min   | attempt intermittent IV push dosing before converting to a drip or to another agent.  |
| Metoprolol tartrate (Lopressor) | Supplied as ampuls, vials, and   | May administer undiluted                                   | Adult: Administer over 1 min   | Continuous ECG and blood  |
|                                 | syringe cartridges as solution for injection   |  | Pediatric: No data   | pressure monitoring required  |
| Corticosteroids                 |  |  |  |   |
| Dexamethasone (Decadron)        | Supplied as vials as solution for injection  | May administer 4 mg/mL or 10 mg/mL concentration undiluted | Adult: Administer over at least 1 min  Pediatricb: Administer over 1 to several minutes  | Rapid administration may be associated with perineal burning or tingling. Can dilute to 0.5 mg/mL in NS and administer up to a 10 mg dose |

| Medication  | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj. | Administration time for IVP/slow IV inj.   | Remarks  |
|---|---|--|--|--|
|   |   |  |  | over 30 s to eliminate the incidence of perineal pruritus.   |
| Hydrocortisone (Solu-Cortef)                      | Reconstitute 100 mg vial with 2 mL of BWFI or bacteriostatic NS. Act-O-vials reconstituted by pressing down on the plastic activator. | No additional dilution is necessary        | Adult: Administer over at least 30 s  For doses ≥ 500 mg, administer over 10 min  Pediatric <sup>b</sup> : Same as adult   | Reconstitute per prescribing information as differences exist between manufacturers.   |
| Methylprednisolone sodium succinate (Solu-Medrol) | Reconstitute with accompanying diluent or bacteriostatic water for injection with benzyl alcohol                                      | No additional dilution is necessary        | Adult: Administration rate is variable, several minutes for doses 10 to 40 mg to at least 5 min for doses ≤ 250 mg  Pediatricb: Doses ≤ 1.8 mg/kg or ≤ 125 mg over 1 to several min; for large doses (≥ 500 mg) administer over 10 min | Administer high-dose therapy (30 mg/kg) by IV administration over at least 30 min. Rapid administration of high doses may precipitate cardiac arrhythmia and sudden death. |
| Diuretics   |   |  |  |  |
| Acetazolamide (Diamox)                            | Reconstitute each 500 mg vial with at least 5 mL SWFI   | No additional dilution is necessary        | Adult: Administer over at least 3 min  Pediatrich: 100 mg/mL at a rate no faster than 500 mg/min   | IM administration not recommended  |
| Bumetanide  | Supplied as vials as solution for injection   | May administer undiluted                   | Adult: Administer over 1 to 2 min  Pediatricb: 0.25 mg/mL over 1 to 2 min  | Oral bioavailability is very good (~80-100%)   |
| Chlorothiazide (Diuril)                           | Reconstitute each 500 mg with at least 18 mL of SWFI  | No additional dilution is necessary        | Adult: Administer over 3 to 5 min (maximum of 500 mg)  Pediatric <sup>b</sup> : Administer slowly over 3 to 5 min as a direct injection  | None of note   |

| Medication             | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj.   | Administration time for IVP/slow IV inj.   | Remarks  |
|------------------------|---|--|--|--|
| Furosemide             | Supplied as vials and prefilled syringes as solution for injection                      | May administer undiluted   | Adult: Administer over 1 to 2 min and no faster than 20 to 40 mg/min  Pediatricb: Administer over 1 to 2 min and no faster than 0.5 mg/kg/min not to exceed 4 mg/min   | Administration faster than 4 mg/min in adults and 0.5 mg/kg/min in pediatrics increases the rate of ototoxicity                                      |
| Rescue agents          |   |  |  |  |
| Atropine               | Supplied as vials and prefilled syringes as solution for injection                      | Administer undiluted   | Adult: Administer as a rapid IV push  Pediatric <sup>b</sup> : Same as adult   | Slow administration may cause paradoxical bradycardia. Additional monitoring of vital signs and / or ECG based on the clinical scenario is required. |
| Flumazenil (Romazicon) | Supplied as vials as solution for injection   | May be administered undiluted. Dilution not required, but may be mixed with D5W, LR, or NS.  | Adult: Administer over 15 to 30 s  Pediatricb: 0.1 mg/mL over 15 s to 30 s; do not exceed 0.2 mg/min   | Administer through a freely running IV infusion into a large vein (to minimize pain at injection site) as a series of small injections.              |
| Mesna (Mesnex)         | Supplied as vials as solution for injection   | Dilute with D5W, NS, LR, D5-<br>0.2% NS, D5-0.33% NS, or<br>D5-0.45% NS.<br>Final conc. of 20 mg/mL  | Adult: Administer over at least 1 min  Pediatricb: Administer as IV bolus per manufacturer; however, current guidelines recommend administration by short IV infusion over 15 to 30 min or by continuous IV infusion | Refer to specific protocol for administration rate and details.  |
| Naloxone (Narcan)      | Supplied as vials, ampuls, cartridges, and prefilled syringes as solution for injection | Can administer undiluted or diluted. For lower doses (0.02 to 0.04 mg), may dilute 1 mL of naloxone 0.4 mg/mL formulation with 9 mL of NS or SWFI for a total volume of 10 mL  Final conc. of 0.04 mg/mL | Adult: Administer undiluted as an IV push over 30 s  Administer diluted as a slow IV push  Pediatricb: 0.4 or 1 mg/mL undiluted over 30 s  | Duration of narcotic action may exceed that of naloxone.   |

| Medication                 | Instructions for reconstitution   | Dilution instructions for IVP/slow IV inj. | Administration time for IVP/slow IV inj.   | Remarks   |
|----------------------------|---|--|--|---|
| Miscellaneous              |   |  |  |   |
| Cosyntropin (Cortosyn)     | Reconstitute 0.25 mg<br>lyophilized powder with 1 mL<br>of NS               | Dilute with 2 to 5 mL of NS                | Adult: Administer over 2 min  Pediatricb: Same as adult  | Note administration differences between the lyophilized powder and solution |
| Diphenhydramine (Benadryl) | Supplied as vials, ampuls, and prefilled syringes as solution for injection | May be given undiluted                     | Adult: Administer no faster than 25 mg/min  Pediatricb: Same as adult  | Monitor for relief of symptoms and mental alertness                         |
| Levothyroxine              | 100 mcg, 200 mcg and 500 mcg vials: reconstitute with 5 mL NS. Shake well.  | No additional dilution is necessary        | Adult: Administer at a maximum rate of 100 mcg/min  Pediatric <sup>b</sup> : Administer as concentration of 40 to 100 mcg/mL in NS over 2 to 3 minutes | None of note  |

<sup>&</sup>lt;sup>a</sup>This list is not inclusive of neonatal administration information. Please refer to the appropriate clinical resources for neonatal information.

Abbreviations: BWFI = bacteriostatic water for injection; D5W = dextrose 5% in water; ECG = electrocardiogram; GERD = gastrointestinal esophageal reflux disease; h = hour; IM = intramuscular; IN = intranasal; IV = intravenous; LR = lactated Ringer solution; min = minute; NA = not applicable; NS = normal saline; PO = by mouth; PONV = postoperative nausea and vomiting; s = second; SC = subcutaneous; SWFI = sterile water for injection

<sup>&</sup>lt;sup>b</sup>Pediatric administration rates provided only; dilution and monitoring information may vary from adults and should be verified with the appropriate clinical resources

### Appendix 1. Antimicrobials that should not be administered as IV push / slow IV injection

| Antibiotic                              | Reason  |
|---|---|
| Amikacin                                | Not recommended based on manufacturer recommendations and/or limited data   |
| Azithromycin (Zithromax)                | Not for IM or IV bolus administration   |
| Ceftaroline (Teflaro)                   | Not recommended based on manufacturer recommendations and/or limited data   |
| Ceftazidime / avibactam (Avycaz)        | Not recommended based on manufacturer recommendations and/or limited data   |
| Ceftolozane / tazobactam (Zerbaxa)      | Not recommended based on manufacturer recommendations and/or limited data   |
| Ciprofloxacin (Cipro)                   | Not recommended based on manufacturer recommendations and/or limited data   |
| Clindamycin (Cleocin)                   | Cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration  |
| Dalbavancin (Dalvance)                  | Not recommended based on manufacturer recommendations and/or limited data   |
| Doxycycline (Doxy 100)                  | Not recommended based on manufacturer recommendations and/or limited data   |
| Eravacycline (Xerava)                   | Not recommended based on manufacturer recommendations and/or limited data   |
| Erythromycin (Erythrocin)               | Do not administer IV push or bolus  |
| Imipenem/cilastatin (Primaxin)          | Do not administer IV push   |
| Lefamulin (Xenleta)                     | Not recommended based on manufacturer recommendations and/or limited data   |
| Levofloxacin                            | Avoid rapid or bolus IV infusion due to risk of hypotension   |
| Linezolid (Zyvox)                       | Not recommended based on manufacturer recommendations and/or limited data   |
| Meropenem/vaborbactam (Vabomere)        | Not recommended based on manufacturer recommendations and/or limited data   |
| Metronidazole (Flagyl)                  | Not recommended based on manufacturer recommendations and/or limited data   |
| Minocycline (Minocin)                   | Infuse over 60 min; avoid rapid administration. Injectable route should only be used if oral route not feasible; caution of thrombophlebitis                          |
| Moxifloxacin (Avelox)                   | Infuse over 60 min; do not infuse by rapid or bolus IV infusion   |
| Oritavancin (Orbactiv)                  | Not recommended based on manufacturer recommendations and/or limited data   |
| Penicillin G (Pfizerpen)                | Not recommended based on manufacturer recommendations and/or limited data   |
| Piperacillin / tazobactam (Zosyn)       | Not recommended based on manufacturer recommendations and/or limited data   |
| Polymyxin B                             | Administration of polymyxin B over a period < 30 min is not recommended, and rapid IV injections should be avoided due to the potential for nephro- or neurotoxicity. |
| Quinupristin / dalfopristin (Synercid)  | Infusion should be completed over 60 min; toxicity may be increased with shorter infusion   |
| Rifampin (Rifadin)                      | Not recommended based on manufacturer recommendations and/or limited data   |
| Tedizolid (Sivextro)                    | Do not administer as an IV push or bolus  |
| Telavancin (Vibativ)                    | Not recommended based on manufacturer recommendations and/or limited data   |
| Tigecycline (Tygacil)                   | Not recommended based on manufacturer recommendations and/or limited data   |
| Trimethoprim-sulfamethoxazole (Bactrim) | Not recommended based on manufacturer recommendations and/or limited data   |
| Vancomycin                              | Recommended adult infusion rate is a minimum of 30 min for every 500 mg administered  |

#### Appendix 2. Antimicrobials that may be administered as IV push / slow IV injection in adults

As highlighted in *Hospital Pharmacy* and validated with current package inserts, there are several antibiotics that have primary literature in adults to support IV push administration but for which IV push administration is not FDA approved. These medications include **cefepime** (Maxipime), ceftriaxone, ertapenem (Invanz), gentamicin, and tobramycin.

While administration via IV push / slow IV injection is not prohibited for the following products, each has associated requirements and/or recommendations that may minimize the benefit(s) generally associated with a push strategy:

- Ampicillin-sulbactam (Unasyn) may be administered via slow injection over 10 to 15 minutes; however, the minimum required product dilution (ie, 33.3 mL for a 1.5 g vial) creates a limitation from a small volume / fluid conservation standpoint.
- The maximum concentration for fosphenytoin (Cerebyx) (25 mg PE/mL; ie, 40 mL minimum total volume for a 1000 mg PE dose) also creates a limitation from a small volume/fluid conservation standpoint. Moreover, although fosphenytoin may be administered at a rate of 150 mg PE/min, severe and fatal cardiovascular events (ie, hypotension and cardiac arrhythmias) may occur with rapid administration. Slower administration reduces the incidence of cardiovascular events as well as severity of paresthesias and pruritis.
- **Phenytoin** has a maximum infusion rate of 50 mg/min (ie, 20-minute infusion for 1 g dose). If rapid IV administration is necessary, fosphenytoin is generally preferred.

#### References:

- 1. Lexi-Drugs. Hudson, OH: Lexicomp. http://online.lexi.com/.
- 2. DailyMed. Bethesda, MD: U.S. National Library of Medicine, National Institutes of Health, Health & Human Services. https://dailymed.nlm.nih.gov/dailymed/.
- 3. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/.
- 4. Facts & Comparisons. St. Louis, MO: Wolters Kluwer Health. https://fco.factsandcomparisons.com/.
- 5. AHFS Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/.
- 6. ASHP Injectable Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/.
- 7. Pediatric Injectable Drugs (The Teddy Bear Book) STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/
- 8. Collins SR. Elsevier's 2022 Intravenous Medications: A Handbook for Nurses and Health Professionals. 38th ed. St. Louis, MO: Elsevier; 2022.
- 9. Spencer S, Ipema H, Hartke P, et al. Intravenous push administration of antibiotics: literature and considerations. Hospital Pharmacy. 2018; 53(3): 157-169.
- 10. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019;39(1):10-39.

**Disclaimer:** The information contained in this document is intended for informational purposes only and is in no way intended to be a substitute for or in any manner to be construed as medical or clinical advice for any patient in your care. The authors, editors, reviewers, contributors and publishers cannot be held responsible for the accuracy or continued accuracy of the information or for any errors or omissions in the document or for any consequences in the form of liability, loss, injury, or damage incurred as a result of the use and application of any of the information, either directly or indirectly. All medical and clinical decisions regarding any patient's care are the responsibility of the patient's physician.

The information contained throughout this document is confidential and proprietary in nature to Vizient, Inc. Use or distribution of this information without Vizient's express written permission is prohibited.

## vizient.

Vizient, Inc. 290 E. John Carpenter Freeway Irving, TX 75062-5146 (800) 842-5146



To learn more, please contact Vizient Center for Pharmacy Practice Excellence, Evidence-Based Medicine Group at pharmacyquestions@vizientinc.com.

As the nation's largest member-driven health care performance improvement company, Vizient provides solutions and services that empower members to deliver high-value care by aligning cost and quality in the critical areas of clinical, operational, and supply chain performance.